SAN DIEGO / Feb 27, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 46th Annual Raymond James Institutional Investors Conference on Tuesday, March 4th.
The live presentation is scheduled to begin at approximately 10:25 AM EST and will be concurrently webcast.
Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference.
About DexCom, Inc.
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.
| Last Trade: | US$75.36 |
| Daily Change: | 0.28 0.37 |
| Daily Volume: | 1,287,663 |
| Market Cap: | US$29.550B |
August 26, 2025 July 30, 2025 July 28, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
